GPT and hyperthyroidism: The most common irAE in the socazolimab plus EC group were hypothyroidism (3.6%), hyperthyroidism (2.8%) and elevated alanine aminotransferase (2.8%); and in the placebo plus EC group were alanine aminotransferase increased (2.8%), aspartate aminotransferase increased (1.2%).